Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. OSE Immunotherapeutics
  6. Summary
    OSE   FR0012127173

OSE IMMUNOTHERAPEUTICS

(OSE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
8.87(c) 8.55(c) 8.64(c) 8.73(c) 9.46(c) Last
26 694 44 937 28 698 52 235 434 196 Volume
-0.45% -3.61% +1.05% +1.04% +8.36% Change
More quotes
Estimated financial data (e)
Sales 2021 15,1 M 17,1 M 17,1 M
Net income 2021 -19,0 M -21,6 M -21,6 M
Net Debt 2021 8,59 M 9,72 M 9,72 M
P/E ratio 2021 -9,20x
Yield 2021 -
Sales 2022 21,7 M 24,6 M 24,6 M
Net income 2022 -14,2 M -16,0 M -16,0 M
Net cash position 2022 53,8 M 60,8 M 60,8 M
P/E ratio 2022 -12,9x
Yield 2022 -
Capitalization 173 M 195 M 195 M
EV / Sales 2021 12,0x
EV / Sales 2022 5,48x
Nbr of Employees 51
Free-Float 63,4%
More Financials
Company
Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the bodyÔÇÖs immunological memory so... 
More about the company
Ratings of OSE Immunotherapeutics
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about OSE IMMUNOTHERAPEUTICS
11/18OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Pha..
AQ
11/17OSE Immunotherapeutics Presented New Translational Data on Tedopi and Preclinical Data ..
AQ
11/17OSE Immunotherapeutics Enrolls First Patient in Phase 2 Study Of Non-Small Cell Lung Ca..
MT
11/17OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Pha..
AQ
11/17OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Pha..
CI
11/16OSE Immunotherapeutics Presented New Translational Data on Tedopi« and Preclinical Data..
AQ
11/16OSE Immunotherapeutics Presented New Translational Data on Tedopi? and Preclinical Data..
CI
11/15OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Dataáon CLEC-1..
GL
11/15OSE Immunotherapeutics Presents First Positive Preclinical Efficacy Data on CLEC-1
CI
10/19OSE IMMUNOTHERAPEUTICS : to Present New Preclinical Data atáUpcoming Bispecific Antibody a..
AQ
10/13OSE IMMUNOTHERAPEUTICS : to Host Today a Virtual 'Immuno-Oncology R&D Day'
AQ
10/13OSE IMMUNOTHERAPEUTICS : to Present New Clinical and Preclinical Data at the Society for I..
GL
10/13OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the Society for ..
GL
10/12OSE IMMUNOTHERAPEUTICS : to Host Today a Virtual “Immuno-Oncology R&D Day”
AQ
10/11GLOBAL MARKETS LIVE : Facebook, Apple, KKR, Adler, Roche...
More news
News in other languages on OSE IMMUNOTHERAPEUTICS
11/17OSE IMMUNO : Invest Securities confirme son conseil
11/17OSE Immunotherapeutics recrute le premier patient de l'étude de phase 2 sur le traiteme..
11/17Les arbres ne montent pas jusqu'au ciel mais on est haut là, non ?
11/17EN DIRECT DES MARCHES : Vinci, GTT, Volkswagen, Tesla, Experian, Activision, Gensight...
11/16OSE IMMUNOTHERAPEUTICS : nouvelles données translationnelles de Tedopi
More news
Analyst Recommendations on OSE IMMUNOTHERAPEUTICS
More recommendations
Chart OSE IMMUNOTHERAPEUTICS
Duration : Period :
OSE Immunotherapeutics Technical Analysis Chart | OSE | FR0012127173 | MarketScreener
Technical analysis trends OSE IMMUNOTHERAPEUTICS
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 9,46 €
Average target price 16,52 €
Spread / Average Target 74,6%
EPS Revisions
Managers and Directors
Alexis Peyroles Chief Executive Officer & Director
Anne-Laure Autret-Cornet Chief Financial & Administrative Officer
Dominique Costantini Chairman & Development Director
Nicolas Poirier Chief Scientific Officer & Director
Sophie Brouard Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OSE IMMUNOTHERAPEUTICS31.39%195
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431